Profile
Fresenius SE & Co. KGaA is a healthcare investor based in Germany, focusing on biopharma, medtech, and care provision sectors. Founded by Eduard Fresenius, the company's venture arm, Fresenius Ventures, is led by Dr. Thomas Michael Thestrup, who joined from Angelini Ventures. Fresenius Ventures sets itself apart by being a strategic corporate venture, aiming to act as a partner and eventual acquirer of startups in related healthcare fields, emphasizing a strong commitment to venture success.
Fresenius Ventures plans to allocate more than 200 million euros over five years into healthcare startups. They invest globally with Europe as a primary sourcing ground, focusing on precision nutrition, microbiome research, new therapeutic modalities, and digital care provision. The venture fund positions itself as an early through growth-stage investor, without specified check sizes, structured with flexibility across its main areas of interest.
Notable investments have not been specified yet, as Fresenius Ventures has just launched. However, the parent company, Fresenius, has been historically involved in strategic investments such as the acquisition of Merck KGaA's biosimilars pipeline and a stake in mAbxience. This strategic fund aims to continue that legacy by leveraging partnerships within its key sectors.
Industry
Fresenius SE & Co. KGaA Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Fresenius Ventures
|
Venture Capital (VC)
Corporate VC (CVC)
|
Biotechnology
Digital
Healthcare Services
Pharmaceuticals
MedTech
|
Seed
Series A
Series B
|
Europe
|
$10-50 m
|
$220 M
|
July 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.